Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC β-lactamase-producing Enterobacteriaceae | Zendy

Indran Balakrishnan | Zendy; Fatih M. Awad-El-Kariem | Zendy; Adnan Aali | Zendy; Prasanna Kumari | Zendy; Rohinton Mulla | Zendy; Benny KwongHuat Tan | Zendy; Daniel Brudney | Zendy; David Ladenheim | Zendy; Anan Ghazy | Zendy; Imran Khan | Zendy; N. Virgincar | Zendy; Shabnam Iyer | Zendy; Stéphane Carryn | Zendy; Sébastien Van de Velde | Zendy

Open Access

Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC β-lactamase-producing Enterobacteriaceae

Author(s) -

Indran Balakrishnan,

Fatih M. Awad-El-Kariem,

Adnan Aali,

Prasanna Kumari,

Rohinton Mulla,

Benny KwongHuat Tan,

Daniel Brudney,

David Ladenheim,

Anan Ghazy,

Imran Khan,

N. Virgincar,

Shabnam Iyer,

Stéphane Carryn,

Sébastien Van de Velde

Publication year - 2011

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkr317

Subject(s) - regimen , carbapenem , antibiotics , medicine , enterobacteriaceae , pneumonia , pseudomonas aeruginosa , cephalosporin , urinary system , microbiology and biotechnology , gastroenterology , biology , bacteria , escherichia coli , gene , biochemistry , genetics

Temocillin, a β-lactam stable against most β-lactamases [including extended-spectrum β-lactamases (ESBLs) and derepressed AmpC cephalosporinases (dAmpC)], has been suggested as an alternative to carbapenems when Pseudomonas can be excluded. Aims To assess temocillin clinical and microbiological cure rates (CCR and MCR) in infection caused by ESBL/dAmpC-producing Enterobacteriaceae and the effects of different dosage regimens.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research